Form 4: Vir Biotechnology Director Sells Shares Under 10b5-1 Plan

Vir Biotechnology Director Vicki L Sato sold 22,000 shares of common stock for a weighted average price of $7.7123 per share under a pre-arranged trading plan.

Summary

• Vicki L Sato, a Director of Vir Biotechnology, Inc. (VIR), sold 22,000 shares of the company's common stock.
• The transaction occurred on February 2, 2026, at a weighted average price of $7.7123 per share.
• The shares were sold in multiple transactions with prices ranging from $7.32 to $7.82, inclusive.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Ms. Sato on March 27, 2025.
• Following this transaction, Ms. Sato beneficially owns 1,144,391 shares of Vir Biotechnology common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale was executed under a pre-arranged Rule 10b5-1 plan, indicating personal financial planning rather than a reaction to new material non-public information, thus mitigating the negative impact typically associated with insider selling.

Negatives

• A director sold 22,000 shares of common stock, which can sometimes be interpreted as a lack of confidence, even if pre-planned.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider sales, even when executed under a Rule 10b5-1 trading plan, are routinely monitored by investors. While such plans are designed to allow insiders to sell shares without being accused of trading on material non-public information, the market often scrutinizes these transactions for any potential signals regarding management's perception of future company prospects or personal financial planning needs.

Stakeholder Impact

• Shareholders may interpret the director's sale of shares as a slightly negative signal, potentially influencing investor sentiment, although the pre-arranged nature of the sale under a 10b5-1 plan often lessens this impact.

Key Dates

Recommendation

The sale by a director, while executed under a pre-arranged 10b5-1 plan, represents a reduction in insider holdings. This event alone does not provide sufficient information to warrant a strong buy or sell recommendation, suggesting a 'hold' position while monitoring further developments and broader company performance.

Keywords

Vir Biotechnology, VIR, Vicki L Sato, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Director